A complete response letter has been issued by FDA in context with the biologics license application for RLX030, Novartis reported. The move is the latest blow to a treatment Novartis yearned would be a keystone of a cardiovascular franchise. Also known as serelaxin, the drug is similar to the naturally occurring human hormone relaxin-2, which has been found to help women adjust to the … [Read more...]
You are here: Home / Archives for cardio drug